These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15326381)
1. Developmental timing of activated erbB2 expression plays a critical role in the induction of mammary tumors. Andrechek ER; Muller WJ Cell Cycle; 2004 Sep; 3(9):1111-3. PubMed ID: 15326381 [TBL] [Abstract][Full Text] [Related]
2. Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. Andrechek ER; Hardy WR; Laing MA; Muller WJ Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4984-9. PubMed ID: 15051890 [TBL] [Abstract][Full Text] [Related]
3. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967 [TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse. Peng M; Ball-Kell SM; Tyner AL Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733 [TBL] [Abstract][Full Text] [Related]
7. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
8. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. Hodgson MC; Vanostran G; Alghamdi S; Poppiti RJ; Agoulnik AI; Agoulnik IU PLoS One; 2013; 8(4):e60455. PubMed ID: 23593223 [TBL] [Abstract][Full Text] [Related]
9. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536 [TBL] [Abstract][Full Text] [Related]
10. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284 [TBL] [Abstract][Full Text] [Related]
11. Targeting Oncogenes into a Defined Subset of Mammary Cells Demonstrates That the Initiating Oncogenic Mutation Defines the Resulting Tumor Phenotype. Holloway KR; Sinha VC; Bu W; Toneff M; Dong J; Peng Y; Li Y Int J Biol Sci; 2016; 12(4):381-8. PubMed ID: 27019623 [TBL] [Abstract][Full Text] [Related]
12. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis. Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265 [TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486 [TBL] [Abstract][Full Text] [Related]
14. Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression. Ling C; Su VM; Zuo D; Muller WJ Cancer Discov; 2012 Jan; 2(1):68-81. PubMed ID: 22585169 [TBL] [Abstract][Full Text] [Related]
15. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Toneff MJ; Du Z; Dong J; Huang J; Sinai P; Forman J; Hilsenbeck S; Schiff R; Huang S; Li Y Neoplasia; 2010 Sep; 12(9):718-26. PubMed ID: 20824048 [TBL] [Abstract][Full Text] [Related]
16. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Hutchinson JN; Jin J; Cardiff RD; Woodgett JR; Muller WJ Cancer Res; 2004 May; 64(9):3171-8. PubMed ID: 15126356 [TBL] [Abstract][Full Text] [Related]
17. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408 [TBL] [Abstract][Full Text] [Related]
18. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291 [TBL] [Abstract][Full Text] [Related]
19. Targeted expression of activated Rac3 in mammary epithelium leads to defective postlactational involution and benign mammary gland lesions. Leung K; Nagy A; Gonzalez-Gomez I; Groffen J; Heisterkamp N; Kaartinen V Cells Tissues Organs; 2003; 175(2):72-83. PubMed ID: 14605486 [TBL] [Abstract][Full Text] [Related]
20. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]